BioSpace3d
Novo Enters the Ring in Legal Fight Against GLP-1 Compounders as Lilly Notches Victory
Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...
Fierce Pharma2d
Texas court decision prevents compounders from producing knockoffs of Eli Lilly's tirzepatide
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Medical Marketing & Media2d
Novo, Lilly and Novartis lead pharma’s stellar ad performance at Oscars
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
InnovationRx: Eli Lilly Has Stockpiled Nearly $550 Million Of Its Next Obesity Drug
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Notable healthcare headlines for the week: Walgreens Boots Alliance, AbbVie and Novo Nordisk in focus
Walgreens jumps as Sycamore agrees to $11.45 a share purchase Sycamore Partners agreed to acquire Walgreens Boots (WBA) in a ...
Ozempic maker says its Australian market could be half the population
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...
US judge denies injunction, restricting copies of Lilly weight-loss drug
A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...
BioSpace2d
Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II
Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...